 PETACH TIKVA, Israel--BUSINESS WIRE-- Can-Fite BioPharma Ltd. NYSE American: CANF TASE: CFBI, a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that Alimentary Pharmacology Therapeutics, a peer reviewed scientific journal focused on gastroenterology and hepatology, published an article titled Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis authored by Can-Fites CEO Dr. Pnina Fishman. 